Search Results - "Raimondi, C."

Targeting PDK1 in cancer by Raimondi, C, Falasca, M

“…Abnormal activation of phosphoinositide 3-kinase (PI3K) signalling is very common in cancer, leading to deregulation of several intracellular processes…”
Get more information

Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16 by Jeha, Sima, Pei, Deqing, Choi, John, Cheng, Cheng, Sandlund, John T, Coustan-Smith, Elaine, Campana, Dario, Inaba, Hiroto, Rubnitz, Jeffrey E, Ribeiro, Raul C, Gruber, Tanja A, Raimondi, Susana C, Khan, Raja B, Yang, Jun J, Mullighan, Charles G, Downing, James R, Evans, William E, Relling, Mary V, Pui, Ching-Hon

“…Despite contemporary treatment, up to 10% of children with acute lymphoblastic leukemia still experience relapse. We evaluated whether a higher dosage of…”
Get full text

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531 by Lamba, Jatinder K, Chauhan, Lata, Shin, Miyoung, Loken, Michael R, Pollard, Jessica A, Wang, Yi-Cheng, Ries, Rhonda E, Aplenc, Richard, Hirsch, Betsy A, Raimondi, Susana C, Walter, Roland B, Bernstein, Irwin D, Gamis, Alan S, Alonzo, Todd A, Meshinchi, Soheil

“…Purpose Gemtuzumab ozogamicin (GO), a CD33-targeted immunoconjugate, is a re-emerging therapy for acute myeloid leukemia (AML). CD33 single nucleotide…”
Get full text

Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel by Creutzig, Ursula, van den Heuvel-Eibrink, Marry M., Gibson, Brenda, Dworzak, Michael N., Adachi, Souichi, de Bont, Eveline, Harbott, Jochen, Hasle, Henrik, Johnston, Donna, Kinoshita, Akitoshi, Lehrnbecher, Thomas, Leverger, Guy, Mejstrikova, Ester, Meshinchi, Soheil, Pession, Andrea, Raimondi, Susana C., Sung, Lillian, Stary, Jan, Zwaan, Christian M., Kaspers, Gertjan J.L., Reinhardt, Dirk

“…Despite major improvements in outcome over the past decades, acute myeloid leukemia (AML) remains a life-threatening malignancy in children, with current…”
Get full text

The transcription factor ERG regulates a low shear stress-induced anti-thrombotic pathway in the microvasculature by Peghaire, C., Dufton, N. P., Lang, M., Salles-Crawley, I. I., Ahnström, J., Kalna, V., Raimondi, C., Pericleous, C., Inuabasi, L., Kiseleva, R., Muzykantov, V. R., Mason, J. C., Birdsey, G. M., Randi, A. M.

“…Endothelial cells actively maintain an anti-thrombotic environment; loss of this protective function may lead to thrombosis and systemic coagulopathy. The…”
Get full text

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation by Pui, Ching-Hon, Campana, Dario, Pei, Deqing, Bowman, W. Paul, Sandlund, John T, Kaste, Sue C, Ribeiro, Raul C, Rubnitz, Jeffrey E, Raimondi, Susana C, Onciu, Mihaela, Coustan-Smith, Elaine, Kun, Larry E, Jeha, Sima, Cheng, Cheng, Howard, Scott C, Simmons, Vickey, Bayles, Amy, Metzger, Monika L, Boyett, James M, Leung, Wing, Handgretinger, Rupert, Downing, James R, Evans, William E, Relling, Mary V

“…This large trial of acute lymphoblastic leukemia in children aimed to determine whether intensive systemic and intrathecal chemotherapy could obviate the need…”
Get full text

Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy by Pui, C-H, Pei, D, Raimondi, S C, Coustan-Smith, E, Jeha, S, Cheng, C, Bowman, W P, Sandlund, J T, Ribeiro, R C, Rubnitz, J E, Inaba, H, Gruber, T A, Leung, W H, Yang, J J, Downing, J R, Evans, W E, Relling, M V, Campana, D

“…To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic…”
Get full text

Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial by Rubnitz, Jeffrey E, Lacayo, Norman J, Inaba, Hiroto, Heym, Kenneth, Ribeiro, Raul C, Taub, Jeffrey, McNeer, Jennifer, Degar, Barbara, Schiff, Deborah, Yeoh, Allen Eng-Juh, Coustan-Smith, Elaine, Wang, Lei, Triplett, Brandon, Raimondi, Susana C, Klco, Jeffery, Choi, John, Pounds, Stanley, Pui, Ching-Hon

“…To identify effective and less toxic therapy for children with acute myeloid leukemia, we introduced clofarabine into the first course of remission induction…”
Get full text

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia by Coustan-Smith, Elaine, MS, Mullighan, Charles G, MD, Onciu, Mihaela, MD, Behm, Frederick G, Prof, Raimondi, Susana C, Prof, Pei, Deqing, MS, Cheng, Cheng, PhD, Su, Xiaoping, PhD, Rubnitz, Jeffrey E, MD, Basso, Giuseppe, Prof, Biondi, Andrea, Prof, Pui, Ching-Hon, Prof, Downing, James R, Prof, Campana, Dario, Prof

“…Summary Background About a fifth of children with acute T-lymphoblastic leukaemia (T-ALL) succumb to the disease, suggesting an unrecognised biological…”
Get full text

Optical and Mechanical Properties of New Ceramic CAD/CAM Materials by Reid, D A, Matis, J I, Lien, W, Raimondi, C J, Arnason, S C, DuVall, N B, Vandewalle, K S

“…The purpose of this study was to compare the optical and mechanical properties of newer ceramic CAD/CAM materials to more established materials on the market…”
Get full text

Ethics of digital therapeutics (DTx) by Refolo, P, Sacchini, D, Raimondi, C, Spagnolo, A G

“…Digital therapeutics (DTx) are a subset of digital health which are often coupled with artificial intelligence (A.I.) techniques and machine learning systems…”
Get more information

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia by Mullighan, Charles G, Collins-Underwood, J Racquel, Phillips, Letha A A, Loudin, Michael G, Liu, Wei, Zhang, Jinghui, Ma, Jing, Coustan-Smith, Elaine, Harvey, Richard C, Willman, Cheryl L, Mikhail, Fady M, Meyer, Julia, Carroll, Andrew J, Williams, Richard T, Cheng, Jinjun, Heerema, Nyla A, Basso, Giuseppe, Pession, Andrea, Pui, Ching-Hon, Raimondi, Susana C, Hunger, Stephen P, Downing, James R, Carroll, William L, Rabin, Karen R

“…Charles Mullighan and colleagues report a recurrent rearrangement of CRLF2 in B-progenitor and Down syndrome-associated acute lymphoblastic leukemia. Their…”
Get full text

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia by Inaba, Hiroto, Coustan-Smith, Elaine, Cao, Xueyuan, Pounds, Stanley B, Shurtleff, Sheila A, Wang, Kathleen Y, Raimondi, Susana C, Onciu, Mihaela, Jacobsen, Jeffrey, Ribeiro, Raul C, Dahl, Gary V, Bowman, W Paul, Taub, Jeffrey W, Degar, Barbara, Leung, Wing, Downing, James R, Pui, Ching-Hon, Rubnitz, Jeffrey E, Campana, Dario

“…In acute myeloid leukemia (AML), initial treatment response by morphologic analysis of bone marrow predicts long-term outcome. Response can now be assessed by…”
Get full text

Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: The plasma RAS wild type "window of opportunity" by Gazzaniga, P, Raimondi, C, Urbano, F, Cortesi, E

Get full text

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial by Rubnitz, Jeffrey E, Prof, Inaba, Hiroto, MD, Dahl, Gary, Prof, Ribeiro, Raul C, Prof, Bowman, W Paul, Prof, Taub, Jeffrey, MD, Pounds, Stanley, PhD, Razzouk, Bassem I, MD, Lacayo, Norman J, MD, Cao, Xueyuan, PhD, Meshinchi, Soheil, MD, Degar, Barbara, MD, Airewele, Gladstone, MD, Raimondi, Susana C, Prof, Onciu, Mihaela, MD, Coustan-Smith, Elaine, MS, Downing, James R, Prof, Leung, Wing, Prof, Pui, Ching-Hon, Prof, Campana, Dario, Prof

“…Summary Background We sought to improve outcome in patients with childhood acute myeloid leukaemia (AML) by applying risk-directed therapy that was based on…”
Get full text

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report by Ostronoff, Fabiana, Othus, Megan, Gerbing, Robert B., Loken, Michael R., Raimondi, Susana C., Hirsch, Betsy A., Lange, Beverly J., Petersdorf, Stephen, Radich, Jerald, Appelbaum, Frederick R., Gamis, Alan S., Alonzo, Todd A., Meshinchi, Soheil

“…NUP98/NSD1 has recently been reported in association with poor outcome in acute myeloid leukemia (AML). Previous studies also observed a high overlap between…”
Get full text

Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia by Pui, C H, Pei, D, Sandlund, J T, Ribeiro, R C, Rubnitz, J E, Raimondi, S C, Onciu, M, Campana, D, Kun, L E, Jeha, S, Cheng, C, Howard, S C, Metzger, M L, Bhojwani, D, Downing, J R, Evans, W E, Relling, M V

“…We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and…”
Get full text

Natural mutations of human XDH promote the nitrite (NO2−)-reductase capacity of xanthine oxidoreductase: A novel mechanism to promote redox health? by Massimo, G., Khambata, R.S., Chapman, T., Birchall, K., Raimondi, C., Shabbir, A., Dyson, Nicki, Rathod, K.S., Borghi, C., Ahluwalia, A.

“…Several rare genetic variations of human XDH have been shown to alter xanthine oxidoreductase (XOR) activity leading to impaired purine catabolism. However,…”
Get full text

Corrigendum to “Natural mutations of human XDH promote the nitrite (NO2−)-reductase capacity of xanthine oxidoreductase: A novel mechanism to promote redox health?” [Redox Biol. 4 (67) (2023) 102864] by Massimo, G., Khambata, R.S., Chapman, T., Birchall, K., Raimondi, C., Shabbir, A., Dyson, Nicki, Rathod, K., Borghi, C., Ahluwalia, A.

Get full text

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group by Tarlock, Katherine, Alonzo, Todd A, Gerbing, Robert B, Raimondi, Susana C, Hirsch, Betsy A, Sung, Lillian, Pollard, Jessica A, Aplenc, Richard, Loken, Michael R, Gamis, Alan S, Meshinchi, Soheil

“…Gemtuzumab ozogamicin (GO), a calicheamicin-conjugated mAb against CD33, has been used in the treatment of acute myeloid leukemia (AML). We evaluated the…”
Get full text